Crossmark

Cost-effectiveness analysis of glofitamab versus rituximab for relapsed or refractory diffuse large B-cell lymphoma patients in China

Published Online: 2025-04-28

Published Print: 2025-10

Authors

Zheng, Hanrui

Zou, Linke

Hu, Ming https://orcid.org/0000-0002-3637-4130
License Information

Text and Data Mining valid from 2025-04-28

Version of Record valid from 2025-04-28
More Information

Article History

Received: 19 February 2025

Accepted: 27 March 2025

First Online: 28 April 2025

Conflicts of interest

: The authors have no conflicts of interest to declare.

Document is current